Effect of the extended dosing interval of anti-TNF-α NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis
Modern Rheumatology · 06.07.2024 · 34 (4) · 678-685
DOI: 10.1093/mr/road097 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Modern Rheumatology, online erschienen am 07.10.2023. Verfasst von Tsutomu Takeuchi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
This article aims to evaluate the effect of the extended dosing interval on the efficacy and safety of ozoralizumab in patients with rheumatoid arthritis (RA).
Methods
In a long-term extension study (HOSHIZORA trial) for patients who had completed a phase II/III study with methotrexate or a phase III study without methotrexate, the dosing interval of ozoralizumab was allowed to extend from every 4 weeks (Q4W) to every 8 weeks (Q8W), at the physician’s discretion, for patients who had maintained a 28-joint disease activity score based on erythrocyte sedimentation rate (DAS28-ESR) <3.2 at the last two time points. The continuation rate, efficacy, and safety were examined in patients who had completed 24 weeks after the change in the dosing interval by the data cut-off point.
Results
Of the 32 patients who maintained DAS28-ESR <3.2 and changed the interval from Q4W to Q8W, 28 (87.5%) remained on Q8W for 24 weeks. At Week 24, the percentages of patients who remained on Q8W and achieved DAS28-ESR <2.6 and <3.2 were 71.9% and 84.4%, respectively. No safety concerns were observed for 24 weeks in the Q8W group.
Conclusions
In patients with RA and maintained DAS28-ESR <3.2 with ozoralizumab, efficacy was sustained and well tolerated after the dosing interval was extended from Q4W to Q8W.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan.
- Keio University School of Medicine, Tokyo, Japan.
- Development Headquarters, Taisho Pharmaceutical Co., Ltd, Tokyo, Japan.
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
ORCID-Profile: Tsutomu Takeuchi, Masafumi Kawanishi, Yoshiya Tanaka
Zitieren
APA
Takeuchi, T., Nakanishi, M., Kawanishi, M., Yamasaki, H., & Tanaka, Y. (2024). Effect of the extended dosing interval of anti-TNF-α NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis. Modern Rheumatology, 34(4), 678-685. https://doi.org/10.1093/mr/road097
Vancouver
Takeuchi T, Nakanishi M, Kawanishi M, Yamasaki H, Tanaka Y. Effect of the extended dosing interval of anti-TNF-α NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis. Modern Rheumatology. 2024;34(4):678-685. doi:10.1093/mr/road097
BibTeX
@article{Takeuchi2024,
author = {Takeuchi, Tsutomu and Nakanishi, Megumi and Kawanishi, Masafumi and Yamasaki, Hironori and Tanaka, Yoshiya},
title = {Effect of the extended dosing interval of anti-TNF-α NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis},
journal = {Modern Rheumatology},
year = {2024},
volume = {34},
number = {4},
pages = {678--685},
doi = {10.1093/mr/road097}
}
EUVIMED